Changing Systems, One Story at a Time: National Summit Reimagines Obesity Care Through Community, Connection, and Compassion
With the theme 'Inspire Change. Build Connection. Advance Wellness.', the summit brings together healthcare professionals, lived experience advocates, and community leaders to explore how we can shift the narrative around health — from judgment to empathy, and from isolation to meaningful support.
'Obesity isn't a character flaw — it's a chronic condition that deserves empathy, science, and dignity,' says Priti Chawla, Executive Director of Obesity Matters.'This summit is about rewriting the narrative — one story, one connection, one person at a time.'
Program highlights include:
Dr. Sean Wharton and Dr. Gillian Mandich on self-compassion and emotional resilience
Dr. Megha Poddar on hormone health across life stages
Dr. Peter Selby facilitating a storytelling session with patient advocates
Dr. David Macklin on Resilience… The Secret Skill to Success
A featured session on Body Image, Stigma, and the Age of Anti-Obesity Medication will be led by Dr. Sandy Van and Sandra Elia, Chair of Obesity Matters.
'We can't let outdated ideals or social media define what health looks like,' says Dr. Sandy Van.'In the era of obesity medication, the pressure to meet unrealistic appearance goals can take a real psychological toll. Effective care must be rooted in evidence, with compassion for both the body and the mind.'
'For too long, people have carried the weight of shame when what they needed was care. At this summit, we are rewriting that story — one rooted in love, science, and the belief that every person deserves access to evidence-based treatment.' — Sandra Elia, Chair, Obesity Matters
For full program details, visit:obesity-matters.com/events/your-health-matters-summit-2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
3 days ago
- Malaysian Reserve
LG LAUNCHES THE OPTIMISM METER TO HELP CANADIANS SPREAD POSITIVITY THROUGH MUSIC
LG invites Canadians to spread the Life's Good message by creating and sharing songs that bring optimism to others TORONTO, Aug. 15, 2025 /CNW/ – LG Electronics Canada, Inc. (LG Canada) wants to strike a chord with Canadians with the launch of the Optimism Meter – a new initiative designed to amplify and track the power of optimism. LG believes that choosing optimism makes Life Good and the Optimism Meter underscores this belief. Research shows a strong connection between music and positive emotions with more than 60% of participants in a recent survey identifying music as their most frequently used non-pharmacological cognitive enhancer.1 With this, LG invites Canadians to contribute to the Optimism Meter, and move the meter, by creating a personalized song, and sharing it with someone special using its new AI music tool, Radio Optimism. Every track shared with #OptimismWins, #LifesGood, and #RadioOptimism fuels the Optimism Meter and helps unlock a $25,000 donation to benefit the MLSE Foundation. 'Music isn't just background sound – it's one of the most powerful emotional tools we have. Whether we're trying to shake off a bad mood, calm our nerves, or tap into joy, people instinctively turn to music to regulate how they feel,' commented Dr. Frank A. Russo, Cognitive Neuroscientist and Director of the Science of Music, Auditory Research and Technology (SMART) Lab. 'It helps us understand our emotions and express what words can't. But perhaps just as important, music connects us to others. Singing or listening together can synchronize heart rates and even brain activity, fostering empathy and trust. Research has shown that music can reduce stress hormones like cortisol, boost bonding hormones like oxytocin, and make us feel closer – especially when we share a musical experience with others. At a neurological level, music activates the same reward circuits in the brain as food, and social connection. This might explain why surveys have consistently found that music is one of the most common non-prescription strategies for managing mood. Music helps us feel better, together.' A global study from LG reveals similar findings. In fact, one-third of Canadians polled believe sharing feelings through emotional content [such as music] and media is one of the most necessary ways to build meaningful connections and ultimately fuel optimism.2 This belief is supported by the understanding that having shared musical experiences, even when asynchronous, can allow people to appreciate their common humanity.3 Furthermore, the act of engaging with music together can release oxytocin, promoting social bonding.4 Radio Optimism transforms this concept into an interactive platform where participants can create and send personalized songs to their loved ones. Users can easily create new songs using AI-powered tools, which are thoroughly trained on a curated music dataset. These tools interpret user prompts to produce unique musical pieces and generate matching album art, providing an engaging and personalized experience. Once generated, these songs can be sent to recipients to deepen their connection and be shared online for others to discover worldwide. Canadians can participate in the Optimism Meter by: Sharing how music fuels their optimism on social media using #OptimismWins #LifesGood #RadioOptimism Creating and sharing personalized songs with Radio Optimism using #RadioOptimism #LifesGood #OptimismWins Visiting to learn more about the campaign and track the progress of the Optimism Meter. Every comment, post, and song shared with the campaign hashtags will contribute to the Optimism Meter, and unlock various milestones, culminating in a $25,000 donation to the MLSE Foundation. Focused on helping youth reach their full potential through sport, MLSE Foundation helps young people facing barriers thrive by providing free access to programs that support physical health, mental well-being, education, and career readiness. One standout program is the dance program at MLSE LaunchPad that empowers young girls through movement and music. With mentorship from North Side Crew, the Toronto Raptors dance team, and a recent showcase win, the program continues to inspire confidence, creativity, and connection. The Optimism Meter is more than just a campaign; it's an invitation to celebrate the joy of music, connect with others, and make a positive impact on communities across Canada. Together, let's spread the good vibes and show that Life's Good when #OptimismWins! Learn more and join the movement at About LG Electronics Canada, Inc. LG Electronics Canada, Inc. is the Canadian subsidiary of LG Electronics Inc., a global sales innovator in technology and manufacturing headquartered in Seoul, South Korea. LG Electronics Canada, with its head office in Toronto, Ontario, is comprised of three business units – Home Appliances Solution, Media Entertainment Solution, and Eco Solution. LG Electronics Canada is focused on delivering award-winning products known for blending style and technology. These innovative products include TVs, audio solutions and portable devices, home appliances, residential and commercial air solutions, computer monitors and laptops, and industry-leading OLED and LED digital display solutions. For more information, visit _______________________________________ 1 Soares, J. M., & Barbosa, M. (2024). The use of pharmacological and non-pharmacological cognitive enhancers in the Portuguese population. Performance Enhancement & Health, 12(1), 100274. 2 Focaldata, Fieldwork conducted from April 29 to May 1, 2025. Sample Size: 5,000 participants across US, UK, Australia, India and Canada, with 1,000 participants in each market, and nationally representative splits by age, gender and region. 3Good, A., Peets, K. F., Choma, B. L., & Russo, F. A. (2022). Singing foreign songs promotes shared common humanity in elementary school children. Journal of Applied Social Psychology, 52(12), 1158–1171. 4 Good, A., & Russo, F. A. (2022). Changes in mood, oxytocin, and cortisol following group and individual singing: A pilot study. Psychology of Music, 50(4), 1340–1347.
Malaysian Reserve
3 days ago
- Malaysian Reserve
Homewood Health Opens Crisis Hotline for Canadians Impacted by Wildfires
GUELPH, ON, Aug. 15, 2025 /CNW/ – In response to the devastating wildfires across Eastern and Atlantic Canada, Homewood Health has activated its 24/7 crisis support line to help anyone affected by the fires. Anyone seeking mental health support may contact the hotline at 1-833-375-0269 for counselling and/or referrals to community resources. Homewood Health's Employee and Family Assistance Program is also available to employees of existing customers by calling their designated toll-free number or visiting We extend our deepest sympathies to everyone impacted by these events and thank all courageous first responders who continue to go above and beyond the call of duty during this time. About Homewood Health: With over 140 years of experience, Homewood Health is at the forefront of mental health and well-being, providing Canadians with an unparalleled continuum of care. We achieve outstanding outcomes every day through our national network of over 6,000 employees and clinical experts working in partnership with leading employers, organizations, and researchers. Our unique and comprehensive stepped care continuum provides the most complete range of mental health services available nationally – from organizational support & training programs to employee assistance & mental health programs, as well as specialized expertise in assessments, return to work, recovery management and family support – all supported by our medical and mental health expertise in our nationally recognized treatment facilities: Homewood Health Centre, Homewood Ravensview and The Residence at Homewood. For more information, please visit
Malaysian Reserve
4 days ago
- Malaysian Reserve
Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 14, 2025 /CNW/ — USA News Group News Commentary – Federal budget cuts have put pressure on cancer research efforts in the United States, but private investment is helping to fill the gap, with oncology ventures securing hundreds of millions in funding so far in 2025. The Senate's recent restoration of $15 million for the Pancreatic Cancer Research Program (PCARP) was a win, yet its earlier elimination underscored the fragility of public support. Against this backdrop, investors are zeroing in on companies with standout science, solid pipelines, and clear regulatory strategies, including Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), Fate Therapeutics, Inc. (NASDAQ: FATE), Inovio Pharmaceuticals, Inc. (NASDAQ: INO), and Nektar Therapeutics (NASDAQ: NKTR). Global Market Insights estimates the global oncology market at US$345.1 billion in 2025 and forecasts it will climb to US$866.1 billion by 2034, growing at a robust 10.8% CAGR. The U.S. alone is expected to contribute $377.1 billion to that total. Vision Research Reports projects an even larger figure for the global cancer drug sector, predicting it will surpass US$900 billion in sales by 2034. Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) has officially entered the most critical phase of its development journey—pursuing a potential registration-enabling trial in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) for its flagship asset, pelareorep. In its latest Q2 2025 report, the company confirmed it has begun formal discussions with the U.S. Food and Drug Administration (FDA) aimed at finalizing a pivotal study design, with trial start-up activities expected to begin as early as Q4 2025. For investors and potential partners, this represents a clear transition from promising clinical data to potential regulatory approval in one of medicine's most challenging cancer types. 'We have turned the corner from proof-of-concept studies and will be sprinting toward regulatory clarity for the remainder of the year,' said Jared Kelly, CEO of Oncolytics. 'As we shore up our intellectual property, get a clear registration path for pelareorep, and allow our GOBLET data to mature, we will establish our position as the only platform immunotherapy in gastrointestinal tumors.' The strategic focus on mPDAC reflects both compelling clinical results and a significant market opportunity. Pelareorep is a systemically delivered oncolytic virus designed to convert immunologically 'cold' tumors—those typically invisible to the immune system—into 'hot' tumors that can respond to immunotherapy. In first-line pancreatic cancer studies, pelareorep-based regimens have demonstrated a notable 21.9% two-year overall survival rate, compared to a 9.2% historical benchmark for standard chemotherapy alone. Even more compelling, when pelareorep was combined with chemotherapy and a checkpoint inhibitor, researchers recorded a 62% objective response rate—particularly significant given that checkpoint inhibitors are not currently approved for use in this indication. These results stem from pelareorep's dual mechanism: it both replicates within cancer cells and activates the body's immune response against tumors. 'This robust data set, amassed from several studies in cancers that have historically resisted immunotherapeutic approaches, provides definitive validation of pelareorep's immune-mediated mechanism of action,' said Dr. Thomas Heineman, Chief Medical Officer of Oncolytics. 'We observed tumor biopsy-confirmed virus replication, immune cell activation, and the recruitment of cytotoxic T cells into the TME—all consistent with the durable responses observed in patients with metastatic PDAC and HR+/HER2- breast cancer who were treated with pelareorep.' Translational data from the GOBLET and AWARE-1 studies demonstrate how pelareorep transforms the tumor microenvironment, increasing PD-L1 expression, heightening interferon signaling, and mobilizing tumor-infiltrating lymphocytes in the blood—changes that correlate with tumor size reduction. This mechanistic validation, combined with survival data from over 1,100 patients across multiple studies, has solidified the company's decision to prioritize this indication. Oncolytics' execution-focused strategy is being led by Jared Kelly and Andrew Aromando, who both played key roles in Ambrx Biopharma's US$2 billion acquisition by Johnson & Johnson. Kelly was appointed CEO earlier this year, while Aromando recently joined as Chief Business Officer. In line with their focus on capital efficiency, the company has terminated its At-the-Market and Equity Line of Credit facilities, citing sufficient resources to advance key milestones without near-term shareholder dilution. Regulatory advantages are already in place to accelerate development. Pelareorep holds Fast Track and Orphan Drug designations for pancreatic cancer from the FDA, meaning the agency has already recognized both the drug's potential and the serious unmet need in this patient population. These statuses streamline review processes and enhance the program's attractiveness to potential pharmaceutical partners. The context underscores the opportunity: pancreatic cancer remains one of the deadliest common cancers, with a five-year survival rate of less than 14%. Unlike other cancers where immunotherapies have transformed treatment, mPDAC has largely resisted immunotherapeutic approaches—making pelareorep's immune-activating mechanism particularly promising for this underserved patient population. Back in July, Oncolytics hosted a key opinion leader event featuring gastrointestinal cancer experts who reviewed survival outcomes for patients and biomarker validation. The expert panel reinforced the view that pelareorep's mechanism of activating innate and adaptive immune responses is both biologically sound and commercially relevant for first-line mPDAC treatment. With this latest milestone, Oncolytics is entering a phase where FDA feedback will shape both clinical plans and potential commercial partnerships. If the agency accepts the company's proposed trial framework centered on an overall survival endpoint, the resulting study could provide definitive proof of pelareorep's market potential in mPDAC. The company expects to provide an updated clinical timeline in Q3 2025, with trial start-up activities potentially beginning as early as Q4 2025. With compelling survival data, regulatory designations in place, and an experienced leadership team driving execution, Oncolytics is positioning pelareorep for a pivotal test in one of oncology's most challenging and underserved markets. CONTINUED… Read this and more news for Oncolytics Biotech at: In other recent industry developments and happenings in the market include: Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) reported strong Q2 2025 results with $60 million in total product revenue, driven primarily by its breakthrough melanoma therapy Amtagvi, which treated over 100 patients in the second quarter. 'Growth for Amtagvi and Proleukin will continue in the second half of 2025 as existing ATC growth continues and large community practices begin treating patients,' said Frederick Vogt, Ph.D., J.D., Interim President and CEO of Iovance. 'We expect our first ex-U.S. regulatory approval imminently and remain on track to provide updates on our clinical programs.' The company's tumor-infiltrating lymphocyte (TIL) therapy—which uses a patient's own immune cells to fight cancer—generated $54.1 million in revenue and represents the first FDA-approved T-cell therapy for solid tumors, offering new hope for advanced melanoma patients who have tried other treatments without success. With expanded clinical trials planned for lung cancer and endometrial cancer, plus international approvals expected in Canada and other markets, Iovance is positioned to bring its innovative cancer treatment to patients worldwide. Fate Therapeutics, Inc. (NASDAQ: FATE) recently announced promising clinical progress for its off-the-shelf CAR T-cell therapy FT819, which showed lasting responses in lupus patients and received FDA clearance to begin trials for a solid tumor program targeting MICA/B proteins. While primarily focused on autoimmune diseases, the company's next-generation FT836 CAR T-cell therapy represents a significant advancement in cancer treatment as it's designed to target solid tumors without requiring harsh conditioning chemotherapy, potentially making the treatment safer and more accessible. 'Building on this momentum, we are also working closely with the FDA under our RMAT designation with the goal of commencing our registrational study for FT819 in SLE and LN in 2026,' said Bob Valamehr, Ph.D., MBA, President and CEO of Fate Therapeutics. 'Additionally, we continue to strengthen our broader pipeline programs with an extended partnership with Ono Pharmaceuticals, and advancements in bringing our next-generation, off-the-shelf CAR T cells with Sword and Shield™ technology toward the clinic.' The company's stem cell-based platform continues to advance multiple programs, including partnerships for HER2-positive solid tumors, positioning Fate as a leader in developing ready-made cancer cell therapies. Inovio Pharmaceuticals, Inc. (NASDAQ: INO) remains on track to submit its application for INO-3107 in the second half of 2025, targeting Recurrent Respiratory Papillomatosis (RRP), a rare cancer-related condition caused by HPV that affects the airways. The company's DNA medicine platform represents a novel approach to treating HPV-related diseases and cancers, with INO-3107 showing significant clinical benefit by reducing the need for repeated surgeries in RRP patients from an average of 4.1 procedures annually to just 0.9 procedures. 'We believe that INO-3107 could become the preferred treatment option for Recurrent Respiratory Papillomatosis (RRP) patients and their physicians—a treatment option with the potential to change the trajectory of this disease,' said Dr. Jacqueline Shea, President and CEO of INOVIO. 'I look forward to building on the significant progress of this past quarter and providing updates as we work toward a potential approval date in mid-2026.' Beyond RRP, Inovio's technology platform is designed to treat various HPV-related cancers and other tumors by teaching the body's immune system to recognize and fight cancer cells. With breakthrough therapy designation from the FDA and plans for a trial involving 100 patients, INO-3107 could become the first DNA-based therapy approved for treating this serious cancer-related condition. Nektar Therapeutics (NASDAQ: NKTR) reported impressive Phase 2b data for rezpegaldesleukin in treating moderate to severe atopic dermatitis, with the company positioning this immune system regulator as a first-in-class treatment for autoimmune diseases. While primarily focused on autoimmune conditions, Nektar's pipeline includes NKTR-255, a treatment designed to boost the immune system's ability to fight cancer, which is being tested in multiple ongoing clinical trials with various partners. 'As a first-in-class, T regulatory cell biologic, rezpegaldesleukin is poised to become an important novel mechanism to treat millions of patients with autoimmune disorders,' said Howard W. Robin, President and CEO of Nektar. 'Finally, we are making significant progress on advancing preclinical studies with a new bispecific antibody, NKTR-0166, which combines the TNFR2 epitope with a validated antibody target.' The company's technology platform creates novel treatments that could potentially address both autoimmune diseases and cancer by enhancing the immune system's cancer-fighting abilities. With additional data expected from hair loss trials in December 2025 and continued development of next-generation programs, Nektar is advancing a unique approach to immune system therapy that could benefit millions of patients with serious diseases. Source: CONTACT: USA NEWS GROUP info@ (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ('MIQ'). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. Logo –
